SARS-CoV-2 mRNA vaccinations fail to elicit humoral and cellular immune responses in patients with multiple sclerosis receiving fingolimod

BACKGROUND: SARS-CoV-2 mRNA vaccination of healthy individuals is highly immunogenic and protective against severe COVID-19. However, there are limited data on how disease-modifying therapies (DMTs) alter SARS-CoV-2 mRNA vaccine immunogenicity in patients with autoimmune diseases. METHODS: As part o...

Descripción completa

Detalles Bibliográficos
Autores principales: Meyer-Arndt, Lil, Braun, Julian, Fauchere, Florent, Vanshylla, Kanika, Loyal, Lucie, Henze, Larissa, Kruse, Beate, Dingeldey, Manuela, Jürchott, Karsten, Mangold, Maike, Maraj, Ardit, Braginets, Andre, Böttcher, Chotima, Nitsche, Andreas, de la Rosa, Kathrin, Ratswohl, Christoph, Sawitzki, Birgit, Holenya, Pavlo, Reimer, Ulf, Sander, Leif E, Klein, Florian, Paul, Friedemann, Bellmann-Strobl, Judith, Thiel, Andreas, Giesecke-Thiel, Claudia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Multiple Sclerosis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9380499/
https://www.ncbi.nlm.nih.gov/pubmed/35835468
http://dx.doi.org/10.1136/jnnp-2022-329395

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9380499/
https://www.ncbi.nlm.nih.gov/pubmed/35835468
http://dx.doi.org/10.1136/jnnp-2022-329395

Ejemplares similares